AR059722A1 - Aminas inhibidoras de renina. composiciones farmaceuticas y usos. - Google Patents
Aminas inhibidoras de renina. composiciones farmaceuticas y usos.Info
- Publication number
- AR059722A1 AR059722A1 ARP070100882A ARP070100882A AR059722A1 AR 059722 A1 AR059722 A1 AR 059722A1 AR P070100882 A ARP070100882 A AR P070100882A AR P070100882 A ARP070100882 A AR P070100882A AR 059722 A1 AR059722 A1 AR 059722A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- ch2ch2
- ch2ch2ch2
- independently selected
- cyclopropyl
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 150000001412 amines Chemical class 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 9
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229910052731 fluorine Inorganic materials 0.000 abstract 2
- 239000011737 fluorine Substances 0.000 abstract 2
- 125000001072 heteroaryl group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- -1 -CH2-CF3 Chemical group 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 150000002222 fluorine compounds Chemical class 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 239000001301 oxygen Chemical group 0.000 abstract 1
- 125000004076 pyridyl group Chemical group 0.000 abstract 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 abstract 1
- 239000002461 renin inhibitor Substances 0.000 abstract 1
- 229940086526 renin-inhibitors Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Chemical group 0.000 abstract 1
- 239000011593 sulfur Chemical group 0.000 abstract 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 abstract 1
- 125000000335 thiazolyl group Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/34—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Gynecology & Obstetrics (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Composiciones farmacéuticas que contienen uno o más de estos compuestos y especialmente su utilizacion como inhibidores de renina. Reivindicacion 1: Un compuesto de la formula (1) donde X representa CH, N+, -O-, W representa un piridinilo o un tiazolilo para-sustituido; V representa -CH2CH2CH2-, -CH2CH2-A-, -CH2-A-CH2, -A-CH2CH2-,CH2CH2CH2CH2-, -A-CH2CH2CH2-, -CH2-A-CH2CH2-, -CH2CH2-A-CH2-, -CH2CH2CH2-A-, -A-CH2CH2-B-, -CH2CH2CH2CH2CH2-, -A-CH2CH2CH2CH2-, -CH2-A-CH2CH2CH2, -CH2CH2-A- CH2CH2, -CH2CH2CH2-A-CH2, -CH2CH2CH2CH2-A-, -A-CH2CH2CH2-B-, -CH2-A-CH2CH2-B-, -A-CH2CH2-B-CH2-, -A-CH2CH2CH2-B-CH2-, -CH2-A-CH2CH2CH2-B-, -O-CH2-Q-, donde Q está unido al grupo U de formula (1), o un pirrolidinilo de la formula (2), U representa arilo no sustituido; arilo mono-, di-, tri- o tetra-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo C1-7, -CF3, halogeno, e hidroxi-alquilo C1-7 o un heteroarilo de cinco miembros con dos heteroátomos seleccionados independientemente entre nitrogeno, oxigeno y azufre, donde dicho radical de heteroarilo está opcionalmente mono-, di- o tri-sustituido, donde los sustituyentes se seleccionan independientemente del grupo formado por alquilo C1-7, alcoxi C1-7, -CF3, -OCF3, y halogeno; Q representa un heteroarilo de cinco miembros con dos o tres heteroátomos seleccionados independientemente entre O y N; A y B representan independientemente entre sí -O- o -S-; R1 representa alquiloC1-7 o cicloalquilo; R2 representa halogeno o alquiloC1-7, R3 representa hidrogeno, halogeno, alquilo C1-7, alcoxi C1-7, o -CF3 y R4 representa hidrogeno; alquil C1-7-O-(CH2)0-4-CH2-; CF3-O-(CH2)0-4-CH2-; R'2N-(CH2)0-4-CH2, donde R' se selecciona independientemente del grupo formado por hidrogeno, alquilo C1-7 (opcionalmente sustituido con uno a tres fluor), ciclopropilo (opcionalmente sustituido con uno a tres fluor), ciclopropil-aIquilo C1-7 (opcionalmente sustituido con uno a tres fluor), y -C(=O)-Rö donde Rö es alquilo C1-4, alcoxi C1-4, -CF3, -CH2-CF3, o ciclopropilo; o R5-C(=O)-(O)0-1-(CH2)0-4-, donde R5 es alquilo C1.4, aIcoxi C1-4, o ciclopropilo; y sus sales.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IB2006050678 | 2006-03-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR059722A1 true AR059722A1 (es) | 2008-04-23 |
Family
ID=38459419
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP070100882A AR059722A1 (es) | 2006-03-03 | 2007-03-02 | Aminas inhibidoras de renina. composiciones farmaceuticas y usos. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20090088457A1 (es) |
| EP (1) | EP2029542A2 (es) |
| JP (1) | JP2009528341A (es) |
| KR (1) | KR20080100382A (es) |
| CN (1) | CN101395135A (es) |
| AR (1) | AR059722A1 (es) |
| AU (1) | AU2007220149A1 (es) |
| BR (1) | BRPI0708487A2 (es) |
| CA (1) | CA2642424A1 (es) |
| IL (1) | IL193831A0 (es) |
| MA (1) | MA30292B1 (es) |
| MX (1) | MX2008011183A (es) |
| NO (1) | NO20084055L (es) |
| TW (1) | TW200800940A (es) |
| WO (1) | WO2007099509A2 (es) |
| ZA (1) | ZA200808419B (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007102127A2 (en) * | 2006-03-08 | 2007-09-13 | Actelion Pharmaceuticals Ltd | New amines |
| US8129538B1 (en) | 2007-03-28 | 2012-03-06 | Takeda Pharmaceutical Company Limited | Renin inhibitors |
| US8343968B2 (en) | 2007-05-24 | 2013-01-01 | Merck Canada Inc. | Case of renin inhibitors |
| CA2695461A1 (en) * | 2007-08-07 | 2009-02-12 | Merck Frosst Canada Ltd. | Renin inhibitors |
| WO2009023964A1 (en) | 2007-08-20 | 2009-02-26 | Merck Frosst Canada Ltd. | Renin inhibitors |
| JP2011500664A (ja) * | 2007-10-15 | 2011-01-06 | カディラ ヘルスケア リミティド | レニン阻害剤 |
| JP4790871B2 (ja) | 2008-05-05 | 2011-10-12 | メルク フロスト カナダ リミテツド | レニン阻害剤としての３，４−置換ピペリジン誘導体 |
| WO2013088452A2 (en) | 2011-11-11 | 2013-06-20 | Sun Pharma Advanced Research Company Ltd. | Quinoline derivatives as renin inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005532371A (ja) * | 2002-06-27 | 2005-10-27 | アクテリオン ファマシューティカルズ リミテッド | レニン阻害剤としての新規なテトラヒドロピリジン誘導体 |
| US20080234305A1 (en) * | 2003-10-09 | 2008-09-25 | Olivier Bezencon | Novel Tetrahydropyridine Derivatives |
| JP2007513107A (ja) * | 2003-12-05 | 2007-05-24 | アクテリオン ファマシューティカルズ リミテッド | ジアザビシクロノネンおよび新側鎖を有するテトラヒドロピリジン誘導体 |
| DE602005020314D1 (de) * | 2004-08-25 | 2010-05-12 | Actelion Pharmaceuticals Ltd | Bicyclononen-derivate als renin-inhibitoren |
-
2007
- 2007-03-01 BR BRPI0708487-0A patent/BRPI0708487A2/pt not_active Application Discontinuation
- 2007-03-01 JP JP2008556906A patent/JP2009528341A/ja active Pending
- 2007-03-01 EP EP07735020A patent/EP2029542A2/en not_active Withdrawn
- 2007-03-01 CA CA002642424A patent/CA2642424A1/en not_active Abandoned
- 2007-03-01 KR KR1020087024153A patent/KR20080100382A/ko not_active Withdrawn
- 2007-03-01 ZA ZA200808750A patent/ZA200808419B/xx unknown
- 2007-03-01 US US12/224,590 patent/US20090088457A1/en not_active Abandoned
- 2007-03-01 WO PCT/IB2007/050671 patent/WO2007099509A2/en not_active Ceased
- 2007-03-01 CN CNA2007800075735A patent/CN101395135A/zh active Pending
- 2007-03-01 MX MX2008011183A patent/MX2008011183A/es not_active Application Discontinuation
- 2007-03-01 AU AU2007220149A patent/AU2007220149A1/en not_active Abandoned
- 2007-03-02 TW TW096107235A patent/TW200800940A/zh unknown
- 2007-03-02 AR ARP070100882A patent/AR059722A1/es unknown
-
2008
- 2008-09-02 IL IL193831A patent/IL193831A0/en unknown
- 2008-09-24 NO NO20084055A patent/NO20084055L/no not_active Application Discontinuation
- 2008-09-26 MA MA31259A patent/MA30292B1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2029542A2 (en) | 2009-03-04 |
| JP2009528341A (ja) | 2009-08-06 |
| US20090088457A1 (en) | 2009-04-02 |
| KR20080100382A (ko) | 2008-11-17 |
| WO2007099509A3 (en) | 2007-12-21 |
| BRPI0708487A2 (pt) | 2011-05-31 |
| WO2007099509A2 (en) | 2007-09-07 |
| CN101395135A (zh) | 2009-03-25 |
| TW200800940A (en) | 2008-01-01 |
| CA2642424A1 (en) | 2007-09-07 |
| IL193831A0 (en) | 2009-08-03 |
| ZA200808419B (en) | 2009-12-30 |
| MX2008011183A (es) | 2008-09-09 |
| AU2007220149A1 (en) | 2007-09-07 |
| MA30292B1 (fr) | 2009-03-02 |
| NO20084055L (no) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR059722A1 (es) | Aminas inhibidoras de renina. composiciones farmaceuticas y usos. | |
| AR059886A1 (es) | Derivados de amidas como inhibidores de renina | |
| AR076264A1 (es) | Triazolopiridinas sustituidas y analogos de estas | |
| CY1117862T1 (el) | Ετεροκυκλικες ενωσεις βενζοδιοξολιου ή βενζοδιοξεπινης ως αναστολεις φωσφοδιεστερασης | |
| AR077598A1 (es) | Compuestos heterociclicos fusionados como modulares de canales ionicos | |
| ECSP088150A (es) | Inhibidores macrociclicos del virus de la hepatitis c | |
| AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| AR111009A1 (es) | INHIBIDORES DE INTEGRINA avb6 | |
| AR058120A1 (es) | Derivados de bencimidazol sustituidos con cromano, una composicion farmaceutica que los contiene y el uso de los mismos en el tratamiento de una enfermedad mediada por la inhibicion de la bomba de acido | |
| PE20121431A1 (es) | Derivados de pirimidina como inhbidores de la enzima cinasa ptk2 | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR079334A1 (es) | Derivados de oxazin amino | |
| AR082508A1 (es) | Derivados de bencimidazoles utiles como inhibidores de prostaglandina esintasa-1 microsomica | |
| CO6270309A2 (es) | Inhibidores tetrahidropiranocromeno de gamma secretasa | |
| AR089774A1 (es) | Derivados de indolizina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen | |
| AR061994A1 (es) | Uso de derivados de imidazol activadores de ampk, su proceso de preparacion y composiciones farmaceuticas que los comprenden | |
| AR059284A1 (es) | Derivados de aminas secundarias | |
| AR099995A1 (es) | Piridilamidinas fungicidas | |
| CO6241108A2 (es) | Derivados de pirrolopiridina y sus uso como inhibidores de bace | |
| AR070459A1 (es) | Derivados de 2-aza-biciclo- [2,2,1] heptano | |
| AR053652A1 (es) | Derivados de indol como inhibidores de proteina quinasas. composiciones farmaceuticas | |
| WO2010005534A3 (en) | Proteasome inhibitors for selectively inducing apoptosis in cancer cells | |
| AR084011A1 (es) | Compuestos nitrogenados heterociclicos utiles para el tratamiento de infecciones por el virus sincitial respiratorio (rsv), proceso para prepararlos y composiciones farmaceuticas que los contienen | |
| AR075332A1 (es) | Dionas ciclicas como herbicidas | |
| AR080703A1 (es) | Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9h-carbazol, moduladores de receptores de prostaglandina d2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de trastornos alergicos o inmunitarios tales como asma. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |